NASDAQ:XFOR X4 Pharmaceuticals (XFOR) Stock Price, News & Analysis → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free XFOR Stock Alerts $1.23 -0.13 (-9.56%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$1.22▼$1.3950-Day Range$0.84▼$1.4752-Week Range$0.57▼$2.58Volume3.51 million shsAverage Volume2.19 million shsMarket Capitalization$206.57 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get X4 Pharmaceuticals alerts: Email Address X4 Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside143.9% Upside$3.00 Price TargetShort InterestHealthy7.34% of Shares Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews Sentiment0.77Based on 2 Articles This WeekInsider TradingSelling Shares$170,428 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.47) to ($0.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.29 out of 5 starsMedical Sector126th out of 909 stocksBiological Products, Except Diagnostic Industry12th out of 155 stocks 3.3 Analyst's Opinion Consensus RatingX4 Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageX4 Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.34% of the outstanding shares of X4 Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverX4 Pharmaceuticals has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in X4 Pharmaceuticals has recently decreased by 13.29%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldX4 Pharmaceuticals does not currently pay a dividend.Dividend GrowthX4 Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreX4 Pharmaceuticals has received a 71.51% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for mental health" and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for X4 Pharmaceuticals is -0.85. Previous Next 3.2 News and Social Media Coverage News SentimentX4 Pharmaceuticals has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for X4 Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 13 people have searched for XFOR on MarketBeat in the last 30 days. This is a decrease of -7% compared to the previous 30 days.MarketBeat Follows3 people have added X4 Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, X4 Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $170,428.00 in company stock.Percentage Held by InsidersOnly 1.08% of the stock of X4 Pharmaceuticals is held by insiders.Percentage Held by Institutions72.03% of the stock of X4 Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for X4 Pharmaceuticals are expected to grow in the coming year, from ($0.47) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of X4 Pharmaceuticals is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of X4 Pharmaceuticals is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioX4 Pharmaceuticals has a P/B Ratio of 3.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. About X4 Pharmaceuticals Stock (NASDAQ:XFOR)X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.Read More XFOR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XFOR Stock News HeadlinesApril 18, 2024 | seekingalpha.comX4 Pharmaceuticals: PDUFA Excitement AheadApril 17, 2024 | msn.comX4 Pharmaceuticals (XFOR) Price Target Increased by 8.75% to 3.62April 24, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 11, 2024 | finance.yahoo.comX4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) market cap decline of US$42m may not have as much of an impact on institutional owners after a year of 7.0% returnsApril 2, 2024 | globenewswire.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2024 | finance.yahoo.comXFOR: PDUFA Date of April 30, 2024 for Mavorixafor for WHIM Syndrome…April 1, 2024 | globenewswire.comX4 Pharmaceuticals to Participate in Upcoming April Investor ConferencesMarch 23, 2024 | seekingalpha.comX4 Pharmaceuticals, Inc. (XFOR) Q4 2023 Earnings Call TranscriptApril 24, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.March 22, 2024 | markets.businessinsider.comBuy Rating Affirmed on X4 Pharmaceuticals Amid Positive Mavorixafor ProspectsMarch 22, 2024 | insidermonkey.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2023 Earnings Call TranscriptMarch 22, 2024 | finance.yahoo.comQ4 2023 X4 Pharmaceuticals Inc Earnings CallMarch 21, 2024 | investorplace.comXFOR Stock Earnings: X4 Pharmaceuticals Beats EPS for Q4 2023March 21, 2024 | finance.yahoo.comX4 Pharmaceuticals Inc (XFOR) Reports Fourth-Quarter and Full-Year 2023 Financial ResultsMarch 21, 2024 | globenewswire.comX4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate UpdateMarch 12, 2024 | globenewswire.comX4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024March 9, 2024 | finance.yahoo.comXFOR Jan 2026 1.000 callMarch 9, 2024 | finance.yahoo.comXFOR Apr 2024 1.500 callMarch 2, 2024 | investing.comX4 Pharmaceuticals Inc (XFOR)March 1, 2024 | globenewswire.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 24, 2024 | benzinga.comX4 Pharmaceuticals Stock (NASDAQ:XFOR), Short Interest ReportFebruary 23, 2024 | finance.yahoo.comXFOR Mar 2024 1.500 putFebruary 22, 2024 | benzinga.comX4 Pharmaceuticals Stock (NASDAQ:XFOR) Insider TradesFebruary 19, 2024 | thestreet.comX4 Pharmaceuticals Inc.February 17, 2024 | finance.yahoo.comXFOR May 2024 1.500 callFebruary 17, 2024 | finance.yahoo.comXFOR Jan 2025 1.500 callFebruary 16, 2024 | finance.yahoo.comXFOR Mar 2024 1.000 putSee More Headlines Receive XFOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today4/24/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:XFOR CUSIPN/A CIK1501697 Webwww.x4pharma.com Phone(857) 529-8300FaxN/AEmployees93Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$5.00 Low Stock Price Target$1.00 Potential Upside/Downside+143.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-101,170,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-170.10% Return on Assets-65.44% Debt Debt-to-Equity Ratio1.07 Current Ratio5.34 Quick Ratio5.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book3.97Miscellaneous Outstanding Shares167,940,000Free Float166,124,000Market Cap$206.57 million OptionableOptionable Beta0.48 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Paula Ragan Ph.D. (Age 54)CEO, President & Director Comp: $963.58kDr. Mary DiBiase Ph.D. (Age 63)Chief Operating Officer Comp: $661.59kDr. Richard Peters M.D. (Age 61)Ph.D., Founder Dr. Renato T. Skerlj Ph.D.FounderDr. Keith T. Flaherty M.D. (Age 53)Founder & Member of Corporate Advisory Board Dr. Arthur Taveras Ph.D. (Age 60)Chief Scientific Officer Dr. Glenn Schulman M.P.H.Pharm. D., Pharm.D., Vice President of Investor Relations & Corporate CommunicationsDr. Robert David Arbeit (Age 76)Senior Vice President of Clinical Development and Translational Research Mr. Mark Baldry M.B.A. (Age 60)Chief Commercial Officer Dr. Christophe Arbet-Engels M.B.A. (Age 62)M.D., Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsCompass TherapeuticsNASDAQ:CMPXElevation OncologyNASDAQ:ELEVAcumen PharmaceuticalsNASDAQ:ABOSInnate PharmaNASDAQ:IPHAOptheaNASDAQ:OPTView All CompetitorsInsiders & InstitutionsKingdon Capital Management L.L.C.Bought 1,500,000 shares on 3/18/2024Ownership: 2.076%Paula RaganSold 49,678 sharesTotal: $43,716.64 ($0.88/share)Mary DibiaseSold 15,409 sharesTotal: $13,559.92 ($0.88/share)Arthur TaverasSold 14,235 sharesTotal: $12,526.80 ($0.88/share)Adam S. MostafaSold 52,500 sharesTotal: $46,200.00 ($0.88/share)View All Insider TransactionsView All Institutional Transactions XFOR Stock Analysis - Frequently Asked Questions Should I buy or sell X4 Pharmaceuticals stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for X4 Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" XFOR shares. View XFOR analyst ratings or view top-rated stocks. What is X4 Pharmaceuticals' stock price target for 2024? 2 Wall Street analysts have issued twelve-month price objectives for X4 Pharmaceuticals' stock. Their XFOR share price targets range from $1.00 to $5.00. On average, they predict the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 143.9% from the stock's current price. View analysts price targets for XFOR or view top-rated stocks among Wall Street analysts. How have XFOR shares performed in 2024? X4 Pharmaceuticals' stock was trading at $0.8385 at the beginning of the year. Since then, XFOR shares have increased by 46.7% and is now trading at $1.23. View the best growth stocks for 2024 here. When is X4 Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our XFOR earnings forecast. How were X4 Pharmaceuticals' earnings last quarter? X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) issued its earnings results on Thursday, March, 21st. The company reported ($0.10) earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.05. What ETFs hold X4 Pharmaceuticals' stock? ETFs with the largest weight of X4 Pharmaceuticals (NASDAQ:XFOR) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS).Simplify Propel Opportunities ETF (SURI). What other stocks do shareholders of X4 Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other X4 Pharmaceuticals investors own include Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), AbbVie (ABBV), Flexion Therapeutics (FLXN), Heat Biologics (HTBX) and SCYNEXIS (SCYX). How do I buy shares of X4 Pharmaceuticals? Shares of XFOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XFOR) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaYour Money is Not SafeAmerican AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding X4 Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
